CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 320 enrolled
Drug / intervention
GSK1562902A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00812981
NCT00812981Phase 3Completed
CompareCT.gov

Non-inferiority Study of GSK Biologicals' Pandemic Influenza Vaccine 1562902A.

GlaxoSmithKline·interventional·Posted Dec 22, 2008·Updated Aug 20, 2018

In Brief

A Phase 3 clinical trial evaluating GSK1562902A for Influenza. Completed, enrolled 320 participants across 1 site.

Detailed Summary

This observer-blind study is designed to show the immunological non-inferiority of Thiomersal-free-processed pandemic influenza vaccine as compared to the Thiomersal-containing-processed pandemic influenza vaccine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesTaiwan
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 22, 2008
Enrollment StartNov 15, 2008
Primary CompletionJun 7, 2009
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.5 years ago

Interventions

GSK1562902Abiological

new-processed (NP), administered intramuscularly in the deltoid region of the non-dominant arm

GSK1562902Abiological

comparative-processed (CP), administered intramuscularly in the deltoid region of the non-dominant arm